Teva Pharmaceutical Industries News

Shares of Teva Pharmaceutical Industries Ltd opened at 38.61 on Friday. Teva Pharmaceutical Industries Ltd has a one year low of $35.00 and a one year high of $51.15. The company has a market cap of $33.629 billion and a P/E ratio of 12.02. Teva Pharmaceutical Industries Ltd last issued its quarterly earnings data on Wednesday, May 9th.

Apple Inc. : Piper Jaffray this morning in a note to investors highlighted the reasons for why it looks for Apple shares to reach $1,000 in the next couple of years.

Other equities research analysts have also recently issued reports about the stock.

May 23--Teva Pharmaceutical Industries Ltd. will enter the personalized medicine field, which will have high efficiency to cost ratios, albeit limited market segments, says Harel Finance analyst Steven Tepper following yesterday's speech by new Teva president and CEO Dr.

Patterson Companies Inc. : After Paterson Companies reported results that beat consensus, Barrington noted the company's 6% growth in sales of dental equipment and software was driven by CEREC and digital radiography products.

HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia JERUSALEM-- --Teva Pharmaceutical Industries Ltd.

Teva Provides Updated 2012 Non-GAAP Financial Outlook; Updated 2012 Non-GAAP Diluted EPS of $5.30 to $5.40 JERUSALEM -- -- On its conference call today, Teva Pharmaceutical Industries Ltd.

The companies whose shares are moving in pre-market trade Thursday are: Hewlett-Packard Company, Activision Blizzard Inc, Teva Pharmaceutical Industries Ltd, Arch Coal Inc, Aviva Plc, Siemens AG and Hewlett-Packard Company stock climbed 8.63 percent to $22.90 in pre-market session.

Shares of Teva Pharmaceutical Industries Ltd opened at 39.18 on Wednesday. Teva Pharmaceutical Industries Ltd has a 52 week low of $35.00 and a 52 week high of $51.15. The company has a market cap of $34.126 billion and a P/E ratio of 12.18. Teva Pharmaceutical Industries Ltd last announced its earnings results on Wednesday, May 9th.

Teva Pharmaceutical Industries Chairman Dr. Phillip Frost bought $5 Million worth of Prolor Biotech stock, according to a filing with the SEC last week.

HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia Teva Pharmaceutical Industries Limited 's Board of Directors Votes to Re-Elect Dr.

Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug Application for CEP-32496, A Novel BRAF Inhibitor SAN DIEGO and JERUSALEM, May 17, 2012 /PRNewswire/ -- Ambit Biosciences and Teva Pharmaceutical Industries Limited today announced the clearance of an Investigational New Drug application with the U.S. Food and Drug ... (more)

Gamida Cell has closed an internal E financing round of $10 million. All major shareholders participated, the company said.

's stock had its "neutral" rating restated by Zacks in a research report issued to clients and investors on Friday.

Dr Weiner has been Teva's head of global research and development for over three decades, most recently as Chief R&D Officer and a member of the Teva Executive Committee.

Teva Pharmaceutical Industries Ltd opened at 42.19 on Thursday. Teva Pharmaceutical Industries Ltd has a 1-year low of $35.00 and a 1-year high of $51.15. The company has a market cap of $37.254 billion and a price-to-earnings ratio of 13.65. Teva Pharmaceutical Industries Ltd last released its earnings data on Wednesday, May 9th.

Ladies and, gentlemen, thank you for standing by. Welcome to the Teva Pharmaceutical Industries Ltd.

HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia Teva Pharmaceutical Industries Limited Appoints Michael Hayden as President of Global Research and Development and Chief Scientific Officer JERUSALEM-- --Teva Pharmaceutical ... (more)

Teva Pharmaceutical Industries posted a 40 percent jump in quarterly profit that beat estimates, boosted by robust sales of its own-branded products and generic medicines in the United States.

Teva Pharmaceutical Industries Limited to Present New Data on Women's Health Products at the American Congress of Obstetricians and Gynecologists Annual Clinical Meeting /PRNewswire/ -- Teva Women's Health today announced new data from the Company's expanding women's health franchise will be featured at the 60th Annual Clinical Meeting of the ... (more)